A Study of Maribavir in Adults With Kidney Failure Who Have a Cytomegalovirus (CMV) Infection After Transplantation
Retrospective Chart Review of Safety Outcomes Associated With Use of Maribavir in Patients With Post-transplant Refractory Cytomegalovirus (CMV) Infection and Comorbid Severe Chronic Kidney Disease (CKD) or Comorbid End-stage Renal Disease (ESRD), Including Patients on Peritoneal Dialysis or Hemodialysis
Sponsor: Takeda
Listed as NCT06243731, this observational or N/A phase trial focuses on Cytomegalovirus (CMV) and Kidney Disease and remains actively recruiting participants. Sponsored by Takeda, it has been updated 7 times since 2025, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.
Status Flow
Change History
7 versions recorded-
Jan 2026 — Present [monthly]
Recruiting
Status: Not Yet Recruiting → Recruiting
-
Aug 2025 — Jan 2026 [monthly]
Not Yet Recruiting
-
Sep 2024 — Aug 2025 [monthly]
Not Yet Recruiting
-
Jul 2024 — Sep 2024 [monthly]
Not Yet Recruiting
-
Jun 2024 — Jul 2024 [monthly]
Not Yet Recruiting
▶ Show 2 earlier versions
-
Apr 2024 — Jun 2024 [monthly]
Not Yet Recruiting
-
Mar 2024 — Apr 2024 [monthly]
Not Yet Recruiting
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- Takeda
For direct contact, visit the study record on ClinicalTrials.gov .
Study Locations
Anderlecht, Belgium , Barakaldo, Spain , Barcelona, Spain , Birmingham, United Kingdom , Bordeaux, France , Brest, France , Créteil, France , Córdoba, Spain , Dorchester, United Kingdom , L'Hospitalet de Llobregat, Spain and 14 more locations